Ardelyx Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Ardelyx ha aumentado sus beneficios a una tasa media anual de 5.5%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 12.7%. Los ingresos han ido creciendo a una tasa media de 73.1% al año.

Información clave

5.5%

Tasa de crecimiento de los beneficios

25.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	73.1%
Rentabilidad financiera	-39.6%
Margen neto	-53.1%
Próxima actualización de resultados	02 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

What To Expect For Ardelyx In The Coming Month

Oct 18

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Oct 04

Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale

Jun 30

Ardelyx Is Down, Long Live Ardelyx

Jan 28

Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher

Dec 02

Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors

Oct 25

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Ardelyx. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:ARDX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	124	-66	134	0
30 Sep 23	134	-27	103	0
30 Jun 23	83	-56	89	0
31 Mar 23	63	-66	81	0
31 Dec 22	52	-67	77	0
30 Sep 22	9	-114	75	0
30 Jun 22	5	-135	73	0
31 Mar 22	4	-153	75	0
31 Dec 21	10	-158	69	0
30 Sep 21	11	-151	66	0
30 Jun 21	12	-125	56	0
31 Mar 21	13	-105	43	0
31 Dec 20	8	-94	33	0
30 Sep 20	8	-85	29	0
30 Jun 20	8	-91	28	0
31 Mar 20	6	-91	26	0
31 Dec 19	5	-95	24	0
30 Sep 19	3	-103	23	22
30 Jun 19	0	-104	22	40
31 Mar 19	0	-100	23	56
31 Dec 18	3	-91	24	0
30 Sep 18	45	-53	24	64
30 Jun 18	44	-50	24	62
31 Mar 18	44	-53	23	66
31 Dec 17	42	-64	23	75
30 Sep 17	0	-106	23	150
30 Jun 17	0	-114	21	134
31 Mar 17	0	-117	21	114
31 Dec 16	0	-112	19	94
30 Sep 16	0	-98	18	0
30 Jun 16	0	-87	17	0
31 Mar 16	18	-50	15	0
31 Dec 15	24	-30	14	39
30 Sep 15	30	-16	12	0
30 Jun 15	38	2	11	0
31 Mar 15	29	-6	9	0
31 Dec 14	32	-3	7	0
30 Sep 14	34	-4	6	1
30 Jun 14	33	-5	5	3
31 Mar 14	31	-7	5	6
31 Dec 13	29	-7	4	0

Ingresos de calidad: ARDX actualmente no es rentable.

Margen de beneficios creciente: ARDX actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ARDX no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 5.5% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ARDX en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ARDX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: ARDX tiene una rentabilidad financiera negativa (-39.6%), ya que actualmente no es rentable.

Ardelyx Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

President notifies of intention to sell stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Insider notifies of intention to sell stock

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

Consensus EPS estimates fall by 47%, revenue upgraded

Price target increased by 7.6% to US$7.08

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Consensus revenue estimates increase by 29%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

Forecast to breakeven in 2024

Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Consensus forecasts updated

Price target increased to US$5.85

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

High number of new directors

Consensus revenue estimates increase by 71%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ardelyx Presents New Data Analyses At Kidney Week 2022, Further Supporting the Clinical Relevance of Xphozah(R) (Tenapanor)

Ardelyx, Inc Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

Ardelyx, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ardelyx, Inc. to Present Poster Presentations on IBSRELA (Tenapanor) for Adult Patients with IBS-C At the American College of Gastroenterology 2022 Annual Scientific Meeting

What To Expect For Ardelyx In The Coming Month

Insider notifies of intention to sell stock

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Consensus forecasts updated

Desglose de ingresos y gastos
Beta